Clinical Trial Update: Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating oral paricalcitol in renal transplant recipients to reduce albuminuria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proteinuria

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: Oslo University Hospital | Conditions: Proteinuria | Phase 3 | Status: COMPLETED